Skip to content
DataLookout
Menu

HYPOG-01NCT03127995

Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence

StatusActive, Not Recruiting
PhaseNot applicable
SponsorUNICANCER
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 10 versions: 7 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 20, 2026
  2. Minor Primary completion date changed from estimate of Dec 2022 to Dec 31, 2022v9
  3. Minor Primary completion date: Sep 2022 to Dec 2022v8
  4. Notable Eligibility criteria revisedv6
  5. Notable Primary completion date: Oct 2021 to Sep 2022v5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 1012 to confirmed 1265
    • Study completion date: Oct 2029 to Sep 2030
    • Site details revised at 28 of 28 sites
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Primary completion date: Sep 2021 to Oct 2021
    • Study completion date: Sep 2029 to Oct 2029
    • Secondary endpoints: details revised at 10 of 11 entries
    • Site details revised at 15 of 28 sites
    v4
  2. Minor Secondary endpoints: details revised at 7 of 11 entriesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Arm Lymphedema
Timeframe: At 3 years

Secondary (10)

Functional Assessment
Aesthetics Assessment-FIBROSIS
Aesthetics Assessment-BIS SCORE
Aesthetics Assessment-Global Cosmestic
CTCAE Toxicity Assessment
Show 5 moreShow less
RTOG/EORTC Toxicity Assessment
Cancer Related Events
Cost-Utility
Quality of Life QLQ-C30
Quality of Life EORTC BR23

Arms and interventions

HYPOFRACTIONATEDExperimental

40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week. If the patient is candidate for a boost it will be provided as follows: * sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions * or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions

NORMOFRACTIONATEDOther

50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week. If the patient is candidate for a boost it will be provided as follows: * sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions * or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions

Radiation: HYPOFRACTIONATED, NORMOFRACTIONATED

Sites

28 sites in 1 country